Medical Condition News

RSS

New oral blood-thinning drugs may have dangerous interactions when taken with prescription drugs : Study

Three new oral blood-thinning drugs nearing approval by the Food and Drug Administration are more convenient than the standard drug Coumadin® because they do not require monthly visits to adjust doses.

2 Jun 2010

CCAC applauds Quebec Ministry of Health's colorectal cancer screening pilot

The Colorectal Cancer Association of Canada (CCAC) applauds the decision of the Quebec Ministry of Health and its Minister Yves Bolduc to implement a colorectal cancer screening pilot in anticipation of launching a province wide colorectal cancer screening program.

2 Jun 2010

Oculus launches Microcyn Negative-Pressure Wound Therapy Solution

Oculus Innovative Sciences, Inc., a commercial medical technology company that designs, produces and markets safe and effective tissue care products based upon the Microcyn® Technology platform, today introduced the Microcyn Negative-Pressure Wound Therapy Solution™ for the U.S. professional healthcare market. Within the pH ranges of 6-7.8 desired for optimum negative-pressure wound therapy, Microcyn is intended for the irrigation and management of wounds via these advanced systems.

2 Jun 2010

Aspirin may not be beneficial for young adults with diabetes

Experts are now recommending that low-dose aspirin therapy to prevent heart attacks be used somewhat more conservatively - that men younger than 50 and women younger than 60, who have diabetes but no other major risk factors, probably not use aspirin.

2 Jun 2010

Meditation-based therapies benefit patients with chronic pain

People who meditate regularly find pain less unpleasant because their brains anticipate the pain less, a new study has found.

2 Jun 2010

Chronix Biomedical to launch new disease detection, monitoring service for cancer researchers at 2010 ASCO

Chronix Biomedical today announced that it will launch a new disease detection and monitoring service for cancer researchers at the upcoming 2010 ASCO Annual Meeting. The "For Investigational Use Only" laboratory-based testing service uses Chronix's breakthrough approach—the Chronix Apoptotic DNA Blood Test—which analyzes apoptotic DNA from dead and dying cells to identify and track ongoing changes associated with specific cancers and other chronic diseases.

2 Jun 2010

Patients at greatest risk of post-PCI bleeding least likely to receive bleeding avoidance strategies

In a study that included data from more than 1.5 million patients, use of vascular closure devices and the anticoagulant bivalirudin were associated with significantly lower bleeding rates for patients following a percutaneous coronary intervention (PCI; procedures such as balloon angioplasty or stent placement used to open narrowed coronary arteries), according to a study in the June 2 issue of JAMA. The researchers also found that patients who may benefit most from these treatments, those at greatest risk of bleeding, were least likely to receive them.

2 Jun 2010

Protox Therapeutics reports positive data from Phase 2b study of PRX302 in BPH

Protox Therapeutics Inc., a leader in the development of receptor targeted fusion proteins, today announced positive six month data from its double-blind placebo controlled Phase 2b study of PRX302 (study name: TRIUMPH) in patients with moderate to severe benign prostatic hyperplasia (BPH) a bothersome urologic condition that affects the quality of life of more than 50 million men worldwide.

2 Jun 2010

Johns Hopkins professor receives $1M MSCRF grant to study glial cells for treating myelin disorders

Q Therapeutics, Inc. announced today that Piotr Walczak, M.D., of Johns Hopkins University has received notification of a $1,000,000 grant to be awarded by the Maryland Stem Cell Research Fund (MSCRF) which will enable further study of Q's human neural glial cell product Q-Cells® in preclinical models of demyelinating disease.

2 Jun 2010

ENMD-2076 demonstrates antitumor activity against murine xenograft models of CRC: Study

EntreMed, Inc., today announced the publication of preclinical results for its clinical-stage Aurora A/angiogenic kinase inhibitor, ENMD-2076, in human colorectal cancer xenograft models. The results of the study, conducted by EntreMed collaborators at the University of Colorado School of Medicine, were published in the June 1, 2010 issue of Clinical Cancer Research (Vol. 16, Issue 11).

2 Jun 2010

Biomoda, Obio sign MOU to establish CLIA-certified clinical laboratory in Ohio

Cancer diagnostics company Biomoda, Inc. and Obio, a corporation formed to pursue public and private funding for cancer research in Ohio, signed a memorandum of understanding to establish a CLIA-certified Biomoda clinical laboratory in Ohio to support ongoing research and development on Biomoda's porphyrin-based assay for the detection of early-stage cancer.

2 Jun 2010

SAGES issues new practice guideline for surgical treatment of GERD

BARRX Medical Inc., a leader in the development of minimally invasive medical devices designed to remove precancerous tissue from within the gastrointestinal tract, reported today that the Society of American Gastrointestinal and Endoscopic Surgeons has issued a new practice guideline for the surgical treatment of gastroesophageal reflux disease. Left untreated, reflux of stomach contents such as acid and bile into the esophagus in GERD patients often leads to injury and chronic inflammation of the lining of the esophagus.

2 Jun 2010

Raptor Pharmaceutical acquires exclusive license to intellectual property for Huntington's Disease treatment

Raptor Pharmaceutical Corp., announced that the Company has acquired an exclusive worldwide license to intellectual property related to the potential treatment of Huntington's Disease from the Weizmann Institute of Science in Israel and Niigata University in Japan. In addition, Raptor has added Professor Lawrence Steinman, M.D., an inventor on the Weizmann patent, to its Advisory Board.

2 Jun 2010

Predictive biomarker for patients with NSCLC

The era of one-size-fits-all medicine will eventually be history; after all it is no news that drugs and treatments do not work the same for everyone. For patients with nonsmall cell lung cancer, a lung cancer that kills approximately 1 million people annually, the treatment currently available is basically the same for all patients, despite the fact that some patients may respond to treatment while others may not.

2 Jun 2010

Alexion Pharmaceuticals plans to launch Soliris in Japan for patients with PNH

Alexion Pharmaceuticals, Inc. and Alexion Pharma International Sàrl today announced that the launch of Soliris (eculizumab) as a treatment for patients with PNH in Japan will begin in the third quarter of 2010, approximately three months earlier than previously expected.

2 Jun 2010

Excess levels of a protein associated with TNF may produce cognitive decline: Studies

Two new studies suggest that excess levels of a protein associated with inflammation, TNF, may produce cognitive decline. TNF regulates both inflammation and brain function. TNF is elevated in the blood in many autoimmune diseases, and in the fluid surrounding the brain in Alzheimer's disease.

2 Jun 2010

Heart attack patients treated beyond maximum recommended time have increased mortality: Study

An examination of the treatment received by patients with myocardial infarction (heart attack) at 80 hospitals in Quebec indicates that those who received either primary percutaneous coronary intervention (PPCI; such as angioplasty) or fibrinolysis (administration of medication to dissolve blood clots) beyond the times recommended in international guidelines had a significantly increased risk of death within 30 days, along with an increased risk of the combined outcome of death or readmission for heart attack or heart failure at one year, according to a study in the June 2 issue of JAMA.

2 Jun 2010

GMC to participate in ProTECT III study of progesterone for emergency treatment of TBI

Geisinger Medical Center will participate in ProTECT III, a groundbreaking National Institute of Health -sponsored research study for the emergency treatment of traumatic brain injuries using the hormone progesterone.

2 Jun 2010

Functional muscle transfer surgery allows people with foot drop to walk without braces

A new surgery that involves an expendable, functioning muscle from the top of the leg and a nerve below the knee can give people with foot drop a new bounce in their step.

2 Jun 2010

UCI study provides blueprint for enhanced treatment of inflammatory diseases

By discovering how adult neural stem cells navigate to injury sites in the central nervous system, UC Irvine researchers have helped solve a puzzle in the creation of stem cell-based treatments: How do these cells know where to go? Tom Lane and Kevin Carbajal of the Sue and Bill Gross Stem Cell Research Center found the answer with the body's immune system.

2 Jun 2010

Medical Condition News

New oral blood-thinning drugs may have dangerous interactions when taken with prescription drugs : Study

CCAC applauds Quebec Ministry of Health's colorectal cancer screening pilot

Oculus launches Microcyn Negative-Pressure Wound Therapy Solution

Aspirin may not be beneficial for young adults with diabetes

Meditation-based therapies benefit patients with chronic pain

Chronix Biomedical to launch new disease detection, monitoring service for cancer researchers at 2010 ASCO

Patients at greatest risk of post-PCI bleeding least likely to receive bleeding avoidance strategies

Protox Therapeutics reports positive data from Phase 2b study of PRX302 in BPH

Johns Hopkins professor receives $1M MSCRF grant to study glial cells for treating myelin disorders

ENMD-2076 demonstrates antitumor activity against murine xenograft models of CRC: Study

Biomoda, Obio sign MOU to establish CLIA-certified clinical laboratory in Ohio

SAGES issues new practice guideline for surgical treatment of GERD

Raptor Pharmaceutical acquires exclusive license to intellectual property for Huntington's Disease treatment

Predictive biomarker for patients with NSCLC

Alexion Pharmaceuticals plans to launch Soliris in Japan for patients with PNH

Excess levels of a protein associated with TNF may produce cognitive decline: Studies

Heart attack patients treated beyond maximum recommended time have increased mortality: Study

GMC to participate in ProTECT III study of progesterone for emergency treatment of TBI

Functional muscle transfer surgery allows people with foot drop to walk without braces

UCI study provides blueprint for enhanced treatment of inflammatory diseases

Redefining control and consistency in anaerobic microbiome workflows

AI in Healthcare: How generative tools are transforming clinical practice

The future of automation: Machine learning–driven hepatocyte and organoid counting

Latest News